AI assistant startup Yutori raises $15m in seed funding
Yutori, a US-based AI assistant startup founded by two former Meta executives, has raised $15m in seed funding.
The funding round was led by Radical Ventures and saw participation from Felicis and more than a dozen angel investors, including Fei-Fei Li and Jeff Dean.
Investors namely Elad Gil, Sarah Guo from Conviction, and Sandhya Venkatachalam from Axiom also took part.
Yutori is co-founded by AI researchers Abhishek Das, Devi Parikh, and Dhruv Batra.
Devi Parikh was previously a senior director at Meta, where she led research in multimodal generative AI, contributing to projects like Llama 3, Make-A-Scene, Make-A-Video, and Emu.
Dhruv Batra also worked as a senior director at Meta, focusing on research related to embodied agents, which supported the multimodal assistant in the Ray-Ban Meta glasses and demos from Boston Dynamics through Meta's FAIR division.
Das' PhD thesis, Building Agents that can See, Talk, and Act, was a finalist for the AAAI/ACM SIGAI doctoral dissertation award in 2020.
The startup focuses on developing personal AI assistants to automate digital tasks. It uses an agent-first approach for building such personal AI assistants to ensure accuracy and reliability across the web.
The funds will be utilised to expedite the development of Yutori's agent-first approach, expand its engineering and design teams, and prepare for the product launch.
Yutori said it plans to offer early adopters the opportunity to participate in a closed beta version of its first product offerings later in 2025.
Yutori co-CEO and co-founder Devi Parikh said: 'Productivity isn't about cramming more into your day — it's about reclaiming your attention for what truly matters, and amplifying the outcomes of the time you give something.
'Yutori's mission is to build the best AI assistants to make space for the meaningful things in life.
The company refines foundation models after training to enhance their autonomy, using a multi-agent system capable of handling multiple tasks and sub-tasks in parallel for high efficiency.
Yutori chief scientist and co-founder Dhruv Batra said: 'What differentiates chatbots from agents is an external environment. The web is the ultimate digital environment — if a task can be done digitally, it can be done via the web.
'But the web is dynamic, non-deterministic, and noisy; which means mistakes are inevitable and the key agentic skill is resilience. Yutori's agent-first approach will unlock superhuman performance on this grand challenge.'
"AI assistant startup Yutori raises $15m in seed funding" was originally created and published by Verdict, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
29 minutes ago
- Business Upturn
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median of 23 months through the latest follow-up, demonstrating the potential of lonvo-z to become the first one-time therapy for most HAE patients Lonvo-z was well tolerated and continues to demonstrate a favorable safety profile The global Phase 3 HAELO trial of lonvo-z has concluded screening ahead of schedule with more than half screened from U.S. sites; Intellia to provide an update on enrollment in the future CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom. 'Today's results underscore the promising potential of Intellia's approach to gene editing therapy – a one-time treatment that was well tolerated and offered a highly differentiated, durable effect for patients suffering from a serious disease,' said Intellia President and Chief Executive Officer John Leonard, M.D. 'Seeing all 10 patients in the Phase 1 portion of this study free from both HAE attacks and chronic therapy at nearly two years of median follow-up is incredibly encouraging. These data fuel our optimism for the outcomes of our ongoing Phase 3 HAELO study, which we expect to report in the first half of 2026, and highlight the strong value we believe it will offer patients, physicians and payers.' 'People living with HAE often report a reduced quality of life because they worry about the likelihood of their next attack, either because they still experience attacks or are reminded of it by their use of chronic therapy,' said Dr. Joshua Jacobs, Medical Director, Allergy and Asthma Clinical Research, Inc. 'Based on the data, it is reasonable to expect lonvo-z could offer patients the potential to be free from both physical HAE attacks and the burden of managing chronic HAE treatment.' In the Phase 1 portion of the study, a one-time dose of 25 mg (N=3), 50 mg (N=4) or 75 mg (N=3) of lonvo-z was administered via intravenous infusion and plasma kallikrein protein levels were measured along with HAE attacks. At the time of the February 12 data cutoff, patients were attack-free and treatment-free for a median of nearly two years. With up to three years of follow-up, a single dose of lonvo-z led to a mean reduction in monthly HAE attack rate of 98% over the study period, compared to pre-treatment baseline. For all 10 patients, deep, dose-dependent and durable reductions in plasma kallikrein protein continued to be observed through the latest assessment. Safety Across all three dose levels, lonvo-z has been well tolerated and continues to demonstrate a favorable safety profile consistent with earlier data presented at EAACI in 2024. The most frequent adverse events during the study period were infusion-related reactions (IRRs). IRRs were mostly Grade 1 and resolved with all patients receiving the full dose. With up to 3 years of follow-up, no treatment-emergent serious adverse events were observed, and no treatment-related adverse events were observed during the period following 28 days after dosing. Clinical Development Plans Intellia's global Phase 3, randomized, double-blind, placebo-controlled HAELO trial is ongoing to assess the safety and efficacy of lonvo-z at the 50 mg dosage. The Company announced today the HAELO trial has successfully completed screening ahead of schedule, with over half of the patients being screened in the United States. The study is no longer recruiting and Intellia will provide an update on enrollment in the future. New and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study is planned to be presented in the second half of 2025. Intellia expects to submit a biologics license application (BLA) in 2026 to support the Company's plans for a U.S. launch in 2027. For more information on HAELO (NCT06634420), please visit About the Lonvoguran Ziclumeran (lonvo-z, also known as NTLA-2002) Clinical Program Intellia's ongoing Phase 1/2 study is evaluating the safety and efficacy of lonvo-z in adults with Type I or Type II hereditary angioedema (HAE). The Phase 1 portion of the study is an international, open-label study designed to identify the dose level of lonvo-z selected for further evaluation in the Phase 2 portion of the study. Enrollment in both portions of the Phase 1/2 study is complete. Intellia dosed the first patient in the global Phase 3, randomized, double-blind, placebo-controlled HAELO trial in January of 2025. Visit (NCT05120830) for more details. About Lonvo-z Based on Nobel Prize-winning CRISPR/Cas9 technology, lonvo-z has the potential to become the first one-time treatment for hereditary angioedema (HAE). Lonvo-z is an investigational in vivo CRISPR-based gene editing therapy designed to prevent HAE attacks by inactivating the kallikrein B1 ( KLKB1 ) gene, which encodes for prekallikrein, the kallikrein precursor protein. Interim Phase 1/2 clinical data showed dramatic reductions in attack rate, as well as consistent, deep and durable reductions in kallikrein levels. Lonvo-z has received five notable regulatory designations, including Orphan Drug and RMAT Designation by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission. About Intellia Therapeutics Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia's deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at and follow us @intelliatx. Forward-Looking Statements This press release contains 'forward-looking statements' of Intellia Therapeutics, Inc. ('Intellia' or the 'Company') within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's beliefs and expectations concerning: the safety, efficacy, success and advancement of its clinical programs for lonvoguran ziclumeran or 'lonvo-z' (also known as NTLA-2002) for hereditary angioedema ('HAE'), including the ability to successfully complete its global Phase 3 HAELO study; its expectation to present additional data regarding lonvo-z, including reporting outcomes of the Phase 3 HAELO study in the first half of 2026 and presenting new and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study of lonvo-z in the second half of 2025; and its expectation to be able to support a biologics license application for lonvo-z for the treatment of HAE by 2026 for a U.S. launch in 2027. Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to Intellia's relationship with third parties, including its contract manufacturers, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to valid third party intellectual property; risks related to Intellia's relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to regulatory agencies' evaluation of regulatory filings and other information related to our product candidates, including lonvo-z; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates, including uncertainties related to regulatory approvals to conduct clinical trials, including our ability to complete the Phase 3 HAELO study for HAE; the risk that any one or more of Intellia's product candidates, including lonvo-z, will not be successfully developed and commercialized; and the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies for the same product candidate or Intellia's other product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia's actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in Intellia's most recent annual report of Form 10-K and quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Intellia's other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law. Intellia Contacts: Investors:Brittany ChavesSenior Manager, Investor Relations [email protected]
Forbes
an hour ago
- Forbes
What Investors Should Know As Meta Gets (Back) Into Crypto
Meta (formerly Facebook) is getting back into crypto Markets and investment trends tend to move in cycles, and the cryptoasset sector is no exception to this rule of the marketplace. As TradFi institutions continue to deploy blockchain affiliated projects, including the launch of a stablecoin by SocGen running on the Ethereum blockchain, the adoption and acceleration of cryptoassets continues virtually unabated. Even as the sentiment toward crypto improves, prices of bitcoin and other cryptocurrencies increase, and the policy landscape pivots toward a pro-growth outlook there remain significant obstacles to mainstream utilization. For example, the tax treatment of crypto is an inhibitor to retail utilization of crypto as a method of payment, and the lack of insurance available for crypto and crypto-adjacent products can make it difficult for institutions to allocate substantial funds to cryptoassets. Against this landscape, exemplified both the increasing adoption and understanding of cryptoassets and applications with the continued limitations to institutional usage, one company stands apart for several reasons. Meta (formerly Facebook) recently has been questioned by Senators Warren and Blumenthal related to its support for the GENIUS Act, and specifically whether or not the firm would block a prohibition on Big Tech firms from owning stablecoin issuers. The specifics of the questioning by the senators will most assuredly change over time, but the letter that has been made publicly available detail that the senators desire specifics as to what the stablecoin plans for Meta are. Let's take a look at why this letter and these questions are important, not only for Meta, but for the cryptoasset marketplace at large. Meta, then operating as Facebook, already attempted to launch of a native stablecoin in 2019 via the Libra project which was subsequently rebranded as Diem. This previous effort occurred during an entirely different economic and policy landscape, and occurred as the organization was still contending with intense scrutiny following the 2016 U.S. Presidential election. Issues that were raised at the time dealt with the potential of a stablecoin issued by Facebook serving to weaken competition, compromise user privacy, and lead to continued fractionalization of which entity or organization sets policy for U.S. monetary and fiscal policy. While the cryptoasset landscape and policy outlook for crypto projects has definitively shifted to a more permissive stance the very same issues that were raised during 2019 loom large as Meta returns to the stablecoin marketplace. Specifically, the letter from the Senators cited the track record of privacy violations, scams, and fake news that continue to occur on the platform as risks that a native stablecoin could amplify. Even as stablecoins increasingly become more mainstream, and are approaching a market capitalization nearing $300 billion, Meta might find many of the same issues that stymied earlier efforts being dragged back to the surface. Since Meta is one of the few returning players to the stablecoin space this provides an opportunity for crypto native stablecoins such as Circle, which continues to ride high following its IPO in June. As Meta edges closer to launching its own stablecoin, the spotlight on Big Tech's role in digital money is about to get a lot brighter, especially as these same tech firms continue to invest billions in AI initiatives. For crypto-native firms like Circle, that's not a threat - it's an opportunity. Meta's sheer size and complicated history with data privacy all but guarantee it will draw intense regulatory scrutiny. And that scrutiny will set a new bar for how stablecoins are viewed and governed both in the U.S. and abroad. That's where Circle can shine. Unlike tech giants pivoting into payments, Circle was built in crypto — with regulatory engagement and transparency as core pillars. While Meta faces inevitable trust questions and regulatory hurdles, Circle can double down on its position as the safer, more compliant alternative. In the coming months, expect firms like Circle to lean into this advantage, especially as institutional partners and consumers alike grow more cautious about Big Tech controlling their money. Notably, the ongoing partnership between Circle and Coinbase – two of the largest crypto native firms that are publicly traded in the U.S. – can also serve to assuage concerns of policymakers. Regardless of this specific stablecoin project plays out the following reality is becoming increasingly clear, and some would say urgent, for the crypto marketplace. With tens of billions flowing into the sector, TradFi firms deploying blockchain based solutions and native stablecoins, and policymakers actively debating the GENIUS Act, the crypto audit and attestation narrative continues to seem stuck. While the AICPA continues to issue guidance and updates related to digital asset attestation, controls, and valuation, the authoritative standard setters remain behind the proverbial curve. As stablecoins become more important and integrated with payment, treasury, and lending systems the urgency for definitive and standardized auditing best practices will continue to elevate in importance.
Hypebeast
an hour ago
- Hypebeast
HAVEN's Summer 2025 Collection Centers on the Pacific Northwest's Terrain
Vancouver-based labelHAVENhas unveiled a coastal campaign for its Summer 2025 collection, returning with a capsule of essentials designed for the warm days and cool nights of Summer in the Pacific Northwest. Utilizing cotton-linen gabardines, Japan denim, and lightweight Super 140s wool, the label offers a range of core garments characterized by the label's functional, minimalist ethos. HAVEN opts for a light and neutral color palette inspired by the woodland coast of Vancouver, led by tones of beige, sage green, brown, off-white, and indigo. The collection is anchored by matching linen gabardine sets, comprising a work jacket that reinterprets the classic military BDU (battle dress uniform) garments. Offered in a dark brown and beige colorway, the jacket's ergonomic tailoring and underarm gussets elevate the utilitarian design with contemporary elegance. In indigo and white, Japanese linen denim shirts and trousers offer a cooling feel and soft hand. The denim Helix Pant features twisted side seams for a sculpted fit and added mobility, and functional details, like slant hand pockets, storm welt back pockets, and snap-adjustable waist tabs. HAVEN tops the collection off with wool Summer shirting, including wool versions of the aforementioned denim shirts in beige, green, and brown checks. Utilizing Super 140s wool, known for its ultra-fine quality, the collection also offers short-sleeve camp collar shirts in the same three colorways. See the gallery above for a closer look at the campaign. HAVEN's Summer 2025 Delivery 1 is out now at the brand'swebsiteand physical store.
